Raymond James & Associates lessened its holdings in Kodiak Sciences Inc. (NASDAQ:KOD) by 7.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,840 shares of the company’s stock after selling 1,868 shares during the period. Raymond James & Associates’ holdings in Kodiak Sciences were worth $2,192,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Ensign Peak Advisors Inc acquired a new stake in shares of Kodiak Sciences in the second quarter worth $93,000. Advisory Services Network LLC purchased a new stake in shares of Kodiak Sciences during the second quarter worth $132,000. Nisa Investment Advisors LLC raised its holdings in shares of Kodiak Sciences by 30.4% during the third quarter. Nisa Investment Advisors LLC now owns 1,610 shares of the company’s stock worth $155,000 after acquiring an additional 375 shares in the last quarter. Compton Capital Management Inc. RI raised its holdings in shares of Kodiak Sciences by 10.0% during the second quarter. Compton Capital Management Inc. RI now owns 2,200 shares of the company’s stock worth $205,000 after acquiring an additional 200 shares in the last quarter. Finally, Amundi purchased a new stake in shares of Kodiak Sciences during the second quarter worth $219,000. 87.00% of the stock is owned by institutional investors and hedge funds.
NASDAQ KOD opened at $65.13 on Friday. Kodiak Sciences Inc. has a fifty-two week low of $59.58 and a fifty-two week high of $171.21. The stock’s 50-day moving average is $90.48 and its two-hundred day moving average is $95.04. The firm has a market cap of $3.37 billion, a P/E ratio of -15.04 and a beta of 1.40.
Several analysts recently issued reports on KOD shares. Citigroup increased their price objective on Kodiak Sciences from $103.00 to $114.00 and gave the stock a “neutral” rating in a report on Thursday, November 11th. BMO Capital Markets increased their price objective on Kodiak Sciences from $104.00 to $114.00 and gave the stock a “market perform” rating in a report on Friday, November 12th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Kodiak Sciences presently has a consensus rating of “Hold” and a consensus target price of $128.63.
In other news, insider John A. Borgeson sold 876 shares of Kodiak Sciences stock in a transaction dated Wednesday, November 10th. The stock was sold at an average price of $115.42, for a total value of $101,107.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jason Ehrlich sold 6,950 shares of Kodiak Sciences stock in a transaction dated Monday, November 22nd. The stock was sold at an average price of $99.15, for a total value of $689,092.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,726 shares of company stock worth $2,175,822. Corporate insiders own 39.70% of the company’s stock.
Kodiak Sciences Profile
Kodiak Sciences, Inc is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD.
Featured Article: What is a management fee?
Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KOD).
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.